Skip to content
Defeat Duchenne Canada Logo

Health Canada: Recommendations for National Rare Disease Strategy

March 30, 2021
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Over the last month, Health Canada has opened up a consultation for organizations like Defeat Duchenne Canada, to provide recommendations on a discussion paper outlining ways to address access to high-cost rare disease drugs in Canada.

There were three different ways to respond:

  1. Questionnaire
  2. Participate in a public town hall
  3. Written submission

Defeat Duchenne Canada submitted input into the questionnaire, engaged in four town halls, and completed a written submission in collaboration with Muscular Dystrophy Canada (MDC) and the Neuromuscular Disease Network for Canada (NMD4C).

Response to the Federal Government on Building a National Strategy for High-Cost Drugs for Rare Diseases

We’re proud to represent the Canadian Duchenne community in consultation with Health Canada on a rare disease strategy. For more information, please contact:

Nicola Worsfold

Director of Research and Advocacy

nicola.worsfold@defeatduchenne.ca

Related Articles